Anaerobutyricum soehngenii improves glycemic control and other markers of cardio-metabolic health in adults at risk of type 2 diabetes
Anaerobutyricum soehngenii (previously Eubacterium hallii) is a butyrate-producing next-generation beneficial microbe generally recognized as safe. Several short-term intervention trials by A. soehngenii L2–7 have shown improvement of insulin sensitivity in prediabetic subjects and type 2 diabetes p...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Gut Microbes |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/19490976.2025.2504115 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850135360796884992 |
|---|---|
| author | Ilias Attaye Julia K. Bird Max Nieuwdorp Sahin Gül Jos F. M. L. Seegers Steven Morrison Stijn Hofkens Hilde Herrema Nam Bui Marie-Luise Puhlmann Willem M. de Vos |
| author_facet | Ilias Attaye Julia K. Bird Max Nieuwdorp Sahin Gül Jos F. M. L. Seegers Steven Morrison Stijn Hofkens Hilde Herrema Nam Bui Marie-Luise Puhlmann Willem M. de Vos |
| author_sort | Ilias Attaye |
| collection | DOAJ |
| description | Anaerobutyricum soehngenii (previously Eubacterium hallii) is a butyrate-producing next-generation beneficial microbe generally recognized as safe. Several short-term intervention trials by A. soehngenii L2–7 have shown improvement of insulin sensitivity in prediabetic subjects and type 2 diabetes patients. To determine the long-term cardiometabolic benefits and safety, we performed a 3-month double-blind, randomized placebo-controlled intervention in 98 prediabetic insulin-resistant adults in Europe and U.S. with daily administration of encapsulated cells of A. soehngenii CH-106, a tetracycline-sensitive isogenic derivative of strain L2–7. Compared to placebo, A. soehngenii-treated subjects showed significantly reduced glycemic variability (1% reduction in the coefficient of variation; p = 0.01) and improved glycemic control (6% reduction in the overall net glycemic action-1; p < 0.05), including reduced serum glycated hemoglobin (HbA1c) levels when including the 4-week washout period (1 mmol/mol reduction; p < 0.05). Moreover, diastolic blood pressure was significantly reduced in all A. soehngenii-treated subjects (3 mm Hg; p < 0.05). The study product was well-tolerated and had no effect on the global intestinal microbiota composition, including alpha and beta-diversity, besides an increased abundance of A. soehngenii in the treatment group, indicative of compliance. The U.S. participants, compared to those in Europe, responded best, notably in the oral glucose tolerance tests (15% improvement in the area-under-the curve of plasma glucose levels; p = 0.039) or coefficient of variation (reduction of 3.1%; p < 0.05). This potentially relates to a more severe prediabetic state in U.S. subjects, associated with significantly reduced (1.5–3.5-fold) relative abundance of Bifidobacterium, Coprococcus, Ruminococcus spp. and two-fold increased relative abundance of Lachnoclostridium spp. In conclusion, daily oral supplementation with A. soehngenii was safe and improved various markers of glycemic control, reduced HbA1c levels and diastolic blood pressure, indicating a novel microbiome-based approach to improve cardio-metabolic health in adults at risk for developing type 2 diabetes.Clinical trial reg. no. NCT04529473, clinicaltrials.govSocial media summary 120 characters: Anaerobutyricum soehngenii supplementation improves #cardio-metabolic health in subjects at risk for type 2 #diabetes |
| format | Article |
| id | doaj-art-d9aa7cd443d54750927a42eda8c26a3c |
| institution | OA Journals |
| issn | 1949-0976 1949-0984 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Gut Microbes |
| spelling | doaj-art-d9aa7cd443d54750927a42eda8c26a3c2025-08-20T02:31:27ZengTaylor & Francis GroupGut Microbes1949-09761949-09842025-12-0117110.1080/19490976.2025.2504115Anaerobutyricum soehngenii improves glycemic control and other markers of cardio-metabolic health in adults at risk of type 2 diabetesIlias Attaye0Julia K. Bird1Max Nieuwdorp2Sahin Gül3Jos F. M. L. Seegers4Steven Morrison5Stijn Hofkens6Hilde Herrema7Nam Bui8Marie-Luise Puhlmann9Willem M. de Vos10Department of Internal and Vascular Medicine, Amsterdam University Medical Centers, The NetherlandsBird Scientific Writing, Wassenaar, The NetherlandsDepartment of Internal and Vascular Medicine, Amsterdam University Medical Centers, The NetherlandsCaelus Health, Zegveld, The NetherlandsCaelus Health, Zegveld, The NetherlandsP2F Ventures, Alton, UKCaelus Health, Zegveld, The NetherlandsDepartment of Internal and Vascular Medicine, Amsterdam University Medical Centers, The NetherlandsDepartment of Internal and Vascular Medicine, Amsterdam University Medical Centers, The NetherlandsLaboratory of Microbiology, Wageningen University, Wageningen, The NetherlandsDepartment of Internal and Vascular Medicine, Amsterdam University Medical Centers, The NetherlandsAnaerobutyricum soehngenii (previously Eubacterium hallii) is a butyrate-producing next-generation beneficial microbe generally recognized as safe. Several short-term intervention trials by A. soehngenii L2–7 have shown improvement of insulin sensitivity in prediabetic subjects and type 2 diabetes patients. To determine the long-term cardiometabolic benefits and safety, we performed a 3-month double-blind, randomized placebo-controlled intervention in 98 prediabetic insulin-resistant adults in Europe and U.S. with daily administration of encapsulated cells of A. soehngenii CH-106, a tetracycline-sensitive isogenic derivative of strain L2–7. Compared to placebo, A. soehngenii-treated subjects showed significantly reduced glycemic variability (1% reduction in the coefficient of variation; p = 0.01) and improved glycemic control (6% reduction in the overall net glycemic action-1; p < 0.05), including reduced serum glycated hemoglobin (HbA1c) levels when including the 4-week washout period (1 mmol/mol reduction; p < 0.05). Moreover, diastolic blood pressure was significantly reduced in all A. soehngenii-treated subjects (3 mm Hg; p < 0.05). The study product was well-tolerated and had no effect on the global intestinal microbiota composition, including alpha and beta-diversity, besides an increased abundance of A. soehngenii in the treatment group, indicative of compliance. The U.S. participants, compared to those in Europe, responded best, notably in the oral glucose tolerance tests (15% improvement in the area-under-the curve of plasma glucose levels; p = 0.039) or coefficient of variation (reduction of 3.1%; p < 0.05). This potentially relates to a more severe prediabetic state in U.S. subjects, associated with significantly reduced (1.5–3.5-fold) relative abundance of Bifidobacterium, Coprococcus, Ruminococcus spp. and two-fold increased relative abundance of Lachnoclostridium spp. In conclusion, daily oral supplementation with A. soehngenii was safe and improved various markers of glycemic control, reduced HbA1c levels and diastolic blood pressure, indicating a novel microbiome-based approach to improve cardio-metabolic health in adults at risk for developing type 2 diabetes.Clinical trial reg. no. NCT04529473, clinicaltrials.govSocial media summary 120 characters: Anaerobutyricum soehngenii supplementation improves #cardio-metabolic health in subjects at risk for type 2 #diabeteshttps://www.tandfonline.com/doi/10.1080/19490976.2025.2504115Anaerobutyricumnext-gen beneficial microbesbutyrate-producing bacteriaprediabetestype 2 diabetescontinuous glucose measurement |
| spellingShingle | Ilias Attaye Julia K. Bird Max Nieuwdorp Sahin Gül Jos F. M. L. Seegers Steven Morrison Stijn Hofkens Hilde Herrema Nam Bui Marie-Luise Puhlmann Willem M. de Vos Anaerobutyricum soehngenii improves glycemic control and other markers of cardio-metabolic health in adults at risk of type 2 diabetes Gut Microbes Anaerobutyricum next-gen beneficial microbes butyrate-producing bacteria prediabetes type 2 diabetes continuous glucose measurement |
| title | Anaerobutyricum soehngenii improves glycemic control and other markers of cardio-metabolic health in adults at risk of type 2 diabetes |
| title_full | Anaerobutyricum soehngenii improves glycemic control and other markers of cardio-metabolic health in adults at risk of type 2 diabetes |
| title_fullStr | Anaerobutyricum soehngenii improves glycemic control and other markers of cardio-metabolic health in adults at risk of type 2 diabetes |
| title_full_unstemmed | Anaerobutyricum soehngenii improves glycemic control and other markers of cardio-metabolic health in adults at risk of type 2 diabetes |
| title_short | Anaerobutyricum soehngenii improves glycemic control and other markers of cardio-metabolic health in adults at risk of type 2 diabetes |
| title_sort | anaerobutyricum soehngenii improves glycemic control and other markers of cardio metabolic health in adults at risk of type 2 diabetes |
| topic | Anaerobutyricum next-gen beneficial microbes butyrate-producing bacteria prediabetes type 2 diabetes continuous glucose measurement |
| url | https://www.tandfonline.com/doi/10.1080/19490976.2025.2504115 |
| work_keys_str_mv | AT iliasattaye anaerobutyricumsoehngeniiimprovesglycemiccontrolandothermarkersofcardiometabolichealthinadultsatriskoftype2diabetes AT juliakbird anaerobutyricumsoehngeniiimprovesglycemiccontrolandothermarkersofcardiometabolichealthinadultsatriskoftype2diabetes AT maxnieuwdorp anaerobutyricumsoehngeniiimprovesglycemiccontrolandothermarkersofcardiometabolichealthinadultsatriskoftype2diabetes AT sahingul anaerobutyricumsoehngeniiimprovesglycemiccontrolandothermarkersofcardiometabolichealthinadultsatriskoftype2diabetes AT josfmlseegers anaerobutyricumsoehngeniiimprovesglycemiccontrolandothermarkersofcardiometabolichealthinadultsatriskoftype2diabetes AT stevenmorrison anaerobutyricumsoehngeniiimprovesglycemiccontrolandothermarkersofcardiometabolichealthinadultsatriskoftype2diabetes AT stijnhofkens anaerobutyricumsoehngeniiimprovesglycemiccontrolandothermarkersofcardiometabolichealthinadultsatriskoftype2diabetes AT hildeherrema anaerobutyricumsoehngeniiimprovesglycemiccontrolandothermarkersofcardiometabolichealthinadultsatriskoftype2diabetes AT nambui anaerobutyricumsoehngeniiimprovesglycemiccontrolandothermarkersofcardiometabolichealthinadultsatriskoftype2diabetes AT marieluisepuhlmann anaerobutyricumsoehngeniiimprovesglycemiccontrolandothermarkersofcardiometabolichealthinadultsatriskoftype2diabetes AT willemmdevos anaerobutyricumsoehngeniiimprovesglycemiccontrolandothermarkersofcardiometabolichealthinadultsatriskoftype2diabetes |